Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Discontinuing TKI Therapy in CML: Focus on Treatment-Free Remission

By: Cordi Craig
Posted: Monday, October 5, 2020

According to a recent study published in Cancers, patients with chronic myeloid leukemia (CML) who achieved a deep molecular response may reach treatment-free remission from the discontinuation of tyrosine kinase inhibitor (TKI) therapy. François-Xavier Mahon, MD, PhD, of the Institut Bergonié, Bordeaux, France, and colleagues suggested that the duration of treatment and the use of first-line second- and third-generation TKIs may be associated with a lower risk of molecular relapse following treatment discontinuation.

Over a period of 10 years, the research team identified 398 patients with chronic-phase CML who were treated with first-line TKI therapy. The patient pool included those treated with front-line imatinib (73%; n = 291) or second- or third-generation TKIs, including nilotinib, dasatinib, and bosutinib (27%; n = 107).

After a median follow-up of 7 years, almost half of the patient pool (46%; n = 182) achieved a sustained deep molecular response of at least 24 months. The researchers found a significant positive association between gender, BCR-ABL1 transcript type, and Sokal and the Europena Treatment Outcome Study (EUTOS) Long-Term Survival risk scores and sustained deep molecular response. The use of first-line TKI therapy did not appear to be significantly associated with a sustained deep molecular response.

At a 47% probability of maintaining molecular response without resuming TKI treatment for 48 months, 95 patients joined a treatment-free remission program and discontinued treatment. The molecular recurrence–free survival rates at 12 and 48 months were 55.1% and 46.9%, respectively. Given the results, the researchers estimated that 28% of patients with CML would be optimal candidates for discontinuing TKI therapy. The duration of TKI therapy and the choice between second- and third-generation and front-line imatinib were the most significant factors associated with molecular recurrence–free survival rates.

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.